Latest news: Quotient Sciences Completes Integration of Drug Substance Into Translational Pharmaceutics Platform

Access Press Release


Quotient Sciences Translational Pharmaceutics Platform

Commemorating 15 years and 500 studies completed.
Dramatically Reduce Your Development Time and Costs with Translational Pharmaceutics®

Quotient Sciences brought meaningful innovation to the pharmaceutical industry in 2008 with Translational Pharmaceutics® – a unique, fully integrated drug development and clinical testing platform, proven to reduce timelines and costs, getting new medicines to patients faster.

By integrating drug substance, drug product, and clinical testing activities all under one organization and a single project manager, Translational Pharmaceutics® breaks down traditional industry silos and accelerates molecules through development. This streamlined approach seamlessly supports our customers’ programs across the entire drug development pathway, from candidate development through to commercialization.

Request a copy of our Translational Pharmaceutics whitepaper.

Learn more about how Quotient Sciences Translational Pharmaceutics platform has been proven to reduce drug development time and costs. Fill out the form to receive a copy of the Tufts Center for the Study of Drug Development (CSDD) whitepaper benchmarking the Translational Pharmaceutics platform versus traditional drug development timelines. The study concluded that for programs utilizing Translational Pharmaceutics™, on average, development timelines were reduced by over 12 months, delivering financial gains of more than $200 million per approved new drug.

Reduce time with Translational Pharmaceutics

Rapidly reach key milestones in your drug development programs.

A rapid make-test cycle that shortens drug development timelines to days rather than months.

Developed in consultation with the US Food and Drug Administration (FDA) and UK Medicines and Healthcare products Regulatory Agency (MHRA), Translational Pharmaceutics® employs rapid ‘make-test’ cycles, where drug products are manufactured, released, and dosed in a clinical study in days rather than months, shortening the time to decision-making human data.

Key benefits of Translational Pharmaceutics:

  • Timeline acceleration of 12 months or more
  • Significant reduction in R&D spend
  • Improved data for better decision making
  • Greater likelihood of of success
  • Simplified supply chain

Expertise that helps shorten time from candidate selection to clinic.

Our expertise in understanding dependencies between drug substance properties, formulation design, and clinical outcomes enables us to enhance development efficiency.

By having both drug substance and drug product manufacturing activities under one organization, we can now deliver integrated chemistry, manufacturing, and controls (CMC) development activities for both pre-clinical and clinical studies in parallel, simplifying the supply chain and shortening the time from candidate selection to clinic by a further 2–4 months.

Interested in learning how your drug development program can benefit from Translational Pharmaceutics®? We can help:

  • Align workflows around drug substance, drug product manufacturing, and clinical testing to shorten the time from candidate development to first-in-human
  • Accelerate molecules from first-in-human to proof-of-concept 
  • Select and optimize clinical formulations
  • Accelerate products to commercial manufacturing

Get More Information

Here's What Clients Are Saying About Translational Pharmaceutics®

"Our small biotech company worked with Quotient Sciences on developing a complex formulation and validating the different iterations of the formulation in PK clinical studies using the Translational Pharmaceutics® approach. The project was successful, and we were generally impressed by the skillsets, professionalism, and courtesy of Quotient Sciences' scientists and other subject experts. We have also chosen to work with Quotient Sciences on two subsequent projects."


Translational pharmaceutics process diagram graphic

On-Demand Webinar

Accelerating Drug Development

The drug development process has been demonstrated to be extremely costly, lengthy, and risky with significant rates of molecule attrition. Despite long-standing efforts by drug developers to operate more efficiently, traditional drug development programs have become costlier on average. A study conducted by the Tufts Center for the Study of Drug Development (CSDD) comparing completed Translational Pharmaceutics® programs to benchmarked industry drug development timelines concluded that programs utilizing Translational Pharmaceutics were reduced by over 12 months with financial gains of more than $200 million per approved new drug.

Watch Webinar